Long term efficacy and safety of etanercept in the treatment of psoriasis and psoriatic arthritis.
Psoriasis is a chronic, immune-mediated inflammatory disease affecting both the skin and joints. Approximately 20% of patients suffer a moderate to severe form of skin disease and up to 30% have joint involvement. Standard therapies for psoriasis include topical medications, phototherapy, and both oral systemic and biological therapies whereas therapies for psoriatic arthritis include nonsteroidal anti-inflammatory drugs followed by disease modifying antirheumatic drugs and/or tumor necrosis factor (TNF)-α inhibitors and interleukin-12/23p40 inhibitors. Treatment of both diseases is typically driven by disease severity. In the past decade, major advances in the understanding of the immunopathogenesis of psoriasis and psoriatic arthritis have led to the development of numerous biological therapies, which have revolutionized the treatment for moderate to severe plaque psoriasis and psoriatic arthritis. Anti-TNF-α agents are currently considered as first line biological therapies for the treatment of moderate to severe psoriasis and psoriatic arthritis. Currently approved anti-TNF-α agents include etanercept, adalimumab, and infliximab for psoriasis and psoriatic arthritis as well as golimumab and certolizumab for psoriatic arthritis. In this article, we aim to evaluate the long term safety and efficacy of etanercept in psoriasis and psoriatic arthritis.
Department of Dermatology, Baylor University Medical Center, Dallas, TX, USA.
Dario
D
Kivelevitch
Department of Dermatology, Baylor University Medical Center, Dallas, TX, USA.
Bobbak
B
Mansouri
Department of Dermatology, Baylor University Medical Center, Dallas, TX, USA.
Alan
A
Menter
biological therapy; etanercept; psoriasis; psoriatic arthritis; safety; tumor necrosis factor